Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib with or without vinorelbine in HER2+ inflammatory breast cancer
NCT01325428Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2011
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of afatinib in inflammatory breast cancer (IBC), sponsored by Boehringer Ingelheim. Started Aug 2011; status: completed.
02
Drugs
afatinib
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT01325428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01325428.